Plasma buprenorphine concentrations after the application of a 70 microg/h transdermal patch in dogs. Preliminary report.
The objective of the present study was to evaluate the plasma concentrations and pharmacokinetics of buprenorphine after transdermal application in dogs (n = 4). A 70 microg/h transdermal buprenorphine patch was applied to the ventral abdomen of four healthy beagles. Blood samples were collected through a preplaced jugular catheter before and at 1, 2, 4, 8, 12, 24, 36, 48 and every 6 h until 108 h after the patch application. Plasma buprenorphine concentrations were measured using a (125)I-labelled radioimmunoassay (RIA) assay. No adverse effects were observed in any of the dogs. Concentrations of buprenorphine were detected in plasma after the application of the transdermal buprenorphine patch on the four experimental animals. Buprenorphine plasma concentrations increased during the first 36 h and then remained in the 0.7-1.0 ng/mL range during the study period. A decrease in plasma buprenorphine concentration was not observed during the study. Although analgesia could not be demonstrated the present study shows the ability of buprenorphine transdermal delivery systems developed for human use to deliver measurable concetrations of buprenorphine in dogs.
Andaluz
A
A
Department of Animal Medicine and Surgery, Autonomous University of Barcelona, 08193 Bellaterra, Barcelona, Spain. anna.andaluz@uab.es
Moll
X
X
Ventura
R
R
Abellán
R
R
Fresno
L
L
García
F
F
D000279:Administration, Cutaneous; D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D000818:Animals; D002047:Buprenorphine / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D004285:Dogs / Q000378:metabolism; D008297:Male; D011863:Radioimmunoassay
D000701:Analgesics, Opioid; D002047:Buprenorphine